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Background: Some n-3 and n-6 polyunsaturated fatty acids (PUFAs) have been suggested to act as anti-atherosclerotic agents. However, primary 
data suggested a relationship between PUFAs and restenosis after percutaneous coronary intervention. Our aim was to test the hypothesis that 
increased PUFAs reduced restenosis after coronary stenting. 
Methods: Samples were obtained from 50 patients who had successful coronary stent implantation and underwent a follow-up angiography 
between 2 and 8 months after stent placement. Eighteen patients took orally eicosapentanoic acid (EPA) at a daily dose of 1.8g. Patients were 
divided into two groups: group 1 showed no in-stent restenosis, group 2 showed in-stent restenosis and needed further intervention due to target 
lesion revascularization. Amounts of EPA, docosahexaenoic acid (DHA), dihomo-gamma-linoleic acid (DGLA), and arachidonic acid (AA) were 
measured in patient blood samples. The percentage change in levels of these PUFAs between before percutaneous coronary intervention and several 
months post-intervention were calculated. 
Results: According to angiography data, target lesion revascularization occurred in 11 patients, while 39 patients did not require further 
intervention. There was no change in the EPA, DHA, and AA levels in patients with or without restenosis. In contrast, the DGLA level was lower in 
patients with restenosis (group 2) compared to that in patients without restenosis (group 1) (-9.1±10.3 % vs. 20.9±5.5 %, respectively, p=0.016). 
We found that there was a significant negative correlation between the change in levels of DGLA and EPA (r=-0.60, p=0.009) in the 18 patients 
taking EPA. 
Conclusion: We have found a significant relationship between serum DGLA levels and in-stent restenosis. Our data suggest that increased levels of 
DGLA plays an important role in prevention of in-stent restenosis.
